Prenumeration
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Oslo, 6 May 2026: Reference is made to the Company’s long-term incentive program for employees ("Option Program") and the Company's program for restricted stock units (“RSUs“) under which board members may be granted, and may receive, all or parts of their board remuneration as RSUs. A settlement period for the Option Program and RSUs commenced on 29 April 2026 at 12:00 hours (CEST) and ended today, on 6 May 2026 at 10:00 hours (CEST).
Exercise of options
In total, 65,500 share options, 51,000 with an exercise price of NOK 0.71 per share and 14,500 with an exercise price of NOK 0.59 per share were exercised, giving the option holders the right to subscribe for 65,500 new shares in total in the Company, each with a nominal value of NOK 0.60.
No primary insiders exercised any share options.
Settlement of RSUs
In total, 52,027 RSUs were settled, of which 26,408 RSUs were settled by current members of the board of directors and 25,619 RSUs were settled by former members of the board of directors, giving the RSUs holders the right to subscribe for 52,027 new shares in total, each with a nominal value of NOK 0.60, at a subscription price of NOK 0.60 per share.
The chairman/board members and primary insiders Damian Marron, Diane Mellett and Thomas Falck have settled 14,012, 2,020 and 10,376 RSUs, respectively, subscribing for the same number of new shares in the Company.
In order to cover tax obligations and payment of exercise price related to the settlement of RSUs, Thomas Falck, board member of the Company, will sell 4,041 of the 10,376 shares issued as RSU settlement. Damian Marron and Diane Mellett as well as former board members of the Company will hold all their shares from their RSU settlements.
A separate stock exchange announcement for further information regarding settlement of the RSUs to the primary insiders will be published.
The RSU holders have previously elected to receive the RSUs as part of their board remuneration instead of cash payment pursuant to resolutions by the annual general meeting (the "AGM") of the Company. The number of RSUs granted was calculated as the NOK amount of the RSU selected portion of the total remuneration to the respective board member, divided by the market price for the shares, calculated as the volume weighted average share price for the 10 trading days prior to the relevant AGM.
Resolution to increase the share capital in the Company
In relation with the exercise of options and settlement of RSUs, the board of directors of the Company has today, on 6 May 2026, in accordance with the board authorisation granted by the extraordinary general meeting on 12 January 2026, resolved to:
- increase the share capital with NOK 39,300.00 by the issuance of 65,500 new shares, each with a nominal value of NOK 0.60 in order to facilitate the exercise of share options; and
- increase the share capital of the Company with NOK 31,216.20 by issuance of 52,027 new shares, each with a nominal value of NOK 0.60, in order to facilitate the settlement of RSUs.
The new share capital of the Company will be NOK 142,903,417.20, divided into 238,172,362 shares, each with a nominal value of NOK 0.60. The share capital increase will be registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret) as soon as practically possible.